RETGenetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center
Open Access
- 1 December 2007
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (12) , 4725-4729
Abstract
Background: Germline RET gene mutations are causative of multiple endocrine neoplasia (MEN) 2 and may be identified by genetic screening. Three different syndromes are distinguished: MEN 2A, when medullary thyroid carcinoma (MTC) is associated with pheochromocytoma and/or parathyroid adenomas; MEN 2B, when accompanied by a marfanoid habitus and/or pheochromocytoma; and familial medullary thyroid carcinoma (FMTC), when only MTC is present. Patients and Methods: During the last 13 yr, we performed RET genetic screening in 807 subjects: 481 with apparently sporadic MTC, 37 with clinical evidence of MEN 2, and 289 relatives. Genomic DNA was extracted from the blood of all subjects, and exons 10, 11, 13, 14, 15, and 16 were analyzed by direct sequencing after PCR. Results: We unexpectedly discovered a germline RET mutation in 35 of 481 (7.3%) apparently sporadic MTC patients. A germline RET mutation was also found in 36 of 37 patients with clinical evidence of hereditary MTC. The distribution of RET mutations in cysteine and noncysteine encoding codons was significantly different in the two groups of patients, with the prevalence of RET mutations in noncysteine codons being higher in MTC that presented as apparently sporadic (P < 0.0001). A total of 34 FMTCs (75.5% of all FMTC) arrived with apparent sporadic MTC, with no familial history of other MTC cases. According to genetic screening and clinical data, our 72 families were classified as follows: 45 FMTC (62.5%), 22 MEN 2A (30.5%), and five MEN 2B (7%). Conclusions: In this large series of MTC, hereditary forms, mainly FMTC, were clinically unsuspected in 7.3% of apparently sporadic cases. As a consequence, the prevalence of FMTC in our series is higher than that previously reported (60 vs. 10%). In these cases, RET mutations were more prevalently located in noncysteine codons. Data derived from our series helped elucidate the role of RET genetic screening for the identification of all forms of MEN 2, and especially for FMTC, which are frequently clinically misdiagnosed as nonheritable, sporadic cases.Keywords
This publication has 19 references indexed in Scilit:
- Familial Medullary Thyroid Carcinoma with Noncysteine RET Mutations: Phenotype-Genotype Relationship in a Large Series of PatientsThe Journal of Clinical Endocrinology & Metabolism, 2001
- Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumoursHuman Molecular Genetics, 1994
- Mutations in the RET proto-oncogene are associated with MEN 2A and FMTCHuman Molecular Genetics, 1993
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2ANature, 1993
- A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10Nature, 1987
- Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entityBritish Journal of Surgery, 1986
- Sipple's Syndrome: Medullary Thyroid Carcinoma, Pheochromocytoma, and Parathyroid DiseaseAnnals of Internal Medicine, 1973
- A calcitonin-secreting medullary thyroid carcinoma associated with mucosal neuromas, marfanoid features, myopathy and pigmentationThe American Journal of Medicine, 1970
- The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid.Proceedings of the National Academy of Sciences, 1968
- MEDULLARY (SOLID) CARCINOMA OF THE THYROID—A CLINICOPATHOLOGIC ENTITY*The Journal of Clinical Endocrinology & Metabolism, 1959